Akeso shares fall up to 31.8% as FDA rejects cancer drug ivonescimab
Hong Kong-listed Akeso saw its stock drop as much as 31.8% on Monday after the US Food and Drug Administration turned down an application for its cancer treatment ivonescimab, unsettling investors about the company's sales prospects.

Summit Therapeutics, the US company holding exclusive rights to develop and commercialise ivonescimab in global markets, said the FDA concluded the drug had not shown “substantial evidence of effectiveness” to support approval.
Ivonescimab is regarded as one of the most prominent innovative drugs to come out of China’s biotech sector in recent years, making the regulatory setback a significant blow to Akeso’s international ambitions.
The sharp share-price decline reflects concern among investors that the rejection could delay or complicate the drug’s path to the US market, a key growth avenue for the company.
For markets, the move highlights how regulatory decisions on single flagship products can trigger outsized swings in Hong Kong-listed biotech stocks, with implications for sentiment toward Chinese healthcare and innovation-drug shares more broadly.
Source: SCMP Business